The best part is this... so they are pretty much saying it should be done by this quarter (i.e before end of September)
In addition, on 25 June 2015, Patrys announced a collaboration with Hefei Co-source including the companies entering into a binding term sheet that covers the exclusive development and commercialisation rights for all oncology indications in China for PAT-SC1. Patrys and Hefei Co-source are moving towards finalising formal documents for this agreement, which are currently anticipated to be effective during the current quarter.
Ann: Response to ASX Price Query, page-3
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
